CONSHOHOCKEN, PA--(Marketwire - February 29, 2012) - NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Jane Hollingsworth, chief executive officer, will present a company overview at Cowen and Company 32nd Annual Health Care Conference on Wednesday, March 7, 2012, at 8:00 a.m. EST. The conference is being held at the Boston Marriott Copley Place in Boston, MA.
A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website for 90 days following the presentation.
NuPathe Inc. is a biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 for the long-term treatment of schizophrenia and bipolar disorder. For more information, please visit our website and our blog at www.nupathe.com. You can also follow us on StockTwits (http://stocktwits.com/NuPatheIR), Twitter (https://twitter.com/#!/NuPathe), SlideShare (http://www.slideshare.net/NuPathe), and LinkedIn (http://www.linkedin.com/company/146880).